Search | Invivogen

Human PD-L1 Antibody - Atezolizumab Biosimilar

Human IgG1 (N298A) - CAS # 1380723-44-3

Comparison of ADCC potency for native and engineered anti-human PD-L1 antibody isotypes

Human BCMA x E. coli β-Gal Bispecific Antibody - Negative Control

Control scFv antibody - Recombinant

Evaluation of T cell activation

Absence of Jurkat-Lucia™ NFAT cell activation using Anti-hBCMA-βgal

Human EpCAM x E. coli β-Gal Bispecific Antibody - Negative Control

Control scFv antibody - Recombinant

Evaluation of T cell activation (ELISA)

Absence of Jurkat-Lucia™ NFAT cell activation using Anti-hEpCAM-βgal

Human EpCAM x Human CD3 Bispecific Antibody

Solitomab scFv antibody - Recombinant

Evaluation of T cell activation (ELISA)

Human BCMA x Human CD3 Bispecific Antibody

Pacanalotamab scFv antibody - Recombinant

Evaluation of T cell activation

E. coli β-Gal x Human CD3 Bispecific Antibody - Negative Control

Control scFv antibody - Recombinant

Activation of Jurkat-Lucia™ NFAT cells with Anti-hCD19-CD3

Anti-βgal-hCD3 does not allow Jurkat-Lucia™ NFAT cell activation

Human CD19 x E. coli β-Gal Bispecific Antibody - Negative control

Control scFv antibody - Recombinant

Activation of Jurkat-Lucia™ NFAT cells with Anti-hCD19-CD3

Absence of Jurkat-Lucia™ NFAT cell activation using Anti-βgal-hCD3

Human CD19 x Human CD3 Bispecific Antibody

Blinatumomab scFv antibody - Recombinant

Evaluation of T cell activation

Target specificity of Anti-hCD19-CD3

Jurkat-Lucia™ NFAT cell activation

Activation of Jurkat-Lucia™ NFAT cells with Anti-hCD19-CD3

Human IgG1 (N298A) Control Antibody

E. coli β-Galactosidase antibody (clone T9C6) - Recombinant

Default product image